Previous news items
Extending STOP-HCV to S.E. Asia through recent awards from the MRC and the Wellcome Trust
STOP-HCV investigators (Prof. Graham Cooke, Chief Investigator and Prof. Eleanor Barnes) have recently secured two awards which will enable the consortium to extend its activities to Vietnam in S.E Asia, where patients are most commonly infected with HCV genotype-6, the most genetically diverse HCV genotype. The awards are: (i) MRC Global Challenges Research Fund (GCRF) SEARCH (South East Asian Research Collaboration in Hepatitis) that will include two small studies of DAA treatment and (ii) a Wellcome Trust collaborative award that will support a large strategic clinical trial. STOP-HCV will generate host and viral genomic data in collaboration with investigators at OUCRU in Ho Chi Minh City.
Viral hepatitis is now the 7th leading cause of death worldwide - findings from the Global Burden of Disease study 2013, published by the Lancet online 6 July 2016.
How to prioritise high-cost HCV treatment? - STOP-HCV investigator Natasha Martin, and others, address this question in an article in the Journal of Hepatology.
STOP-HCV-1 - STOP-HCV investigator, Dr Graham Cooke, has secured funding from the NIHR Efficacy and Mechanism Evaluation programme to undertake a clinical study (STOP-HCV-1) to look at stratification within short-course, all-oral direct-acting antiviral HCV treatment regimes, for Gt1 HCV infected patients with mild liver disease.
High-throughput whole-genome HCV sequencing - STOP-HCV researchers have published a method for high-throughput detection of HCV, and other diverse pathogens, in F1000Research (13 October 2015). This enrichment probe based method provides efficient detection and sequencing of any HCV genome, including mixtures and intra-host variants, in a single experiment.
Gilead Sciences BOSON study - exciting clinical results from the BOSON study - an academic/industrial collaboration within STOP-HCV - have been published online (03 August 2015) in Gastroenterology.
July/August 2015 - STOP-HCV researchers Dr John McLauchlan and Dr Graham Cooke comment on the work of STOP-HCV, and the current treatment landscape for HCV, in pieces published by the MRC and Medicine at Imperial.
Gilead Sciences BOSON trial - clinical findings were presented by Professor Graham Foster at the annual European Association for the Study of Liver Disease meeting in Vienna, 22-26 April 2015.
'HCV Research Consortia: A 10,000 UK patient cohort delivering translational research' - STOP-HCV presented this at the BVHG Showcase Event in Manchester on 5 June 2015.
Gilead Sciences BOSON trial - the Clinical Research Network's 'Spotlight on hepatitis research' highlights the importance of the academic-industrial collaboration within STOP-HCV.
STOP-HCV award now active
The official start date for STOP-HCV was 16th September 2013. Work has now begun to meet the consortiums aims.